今年年初，国际顶尖学术期刊《Cell》在线发表了广西医科大学靶向肿瘤学国家重点实验室主任赵永祥教授团队的最新研究成果：“Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients”（静脉注射溶瘤病毒疗法 ...

A phase 1/2 trial reveals sacituzumab tirumotecan shows manageable toxicity and promising antitumor activity in patients with ...

Shockwave Medical's Reducer implant could "offer an option for patients with no options," Chief Medical Officer Dr. Nick West ...

During a live event, Nathan Denlinger, DO, MS, discussed outcomes of the ZUMA-7 trial in diffuse large B-cell lymphoma.

Despite decades of research, multiple myeloma remains an incurable disease. A wide array of therapies, such as proteasome ...

In sham-controlled trials, the device appears less beneficial than it has been in single-arm, observational studies.

Study identifies aphthous stomatitis as a predictor of colchicine resistance in SURF and supports IL-1 inhibitors for ...

A new study published in The Bone and Joint Journal showed that for the diagnosis of infections in the lower limbs associated ...

A lthough most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it ...

The combination of standard chemotherapy-based salvage therapy followed by high-dose chemotherapy with ASCT cures about half of patients with relapsed/refractory HL. 2, 32 Prognostic factors for ASCT ...